G1 Therapeutics, Inc. (GTHX) Stock Analysis

G1 Therapeutics, Inc. (GTHX) Healthcare & Pipeline Overview

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for cancer, featuring the commercial product COSELA for chemotherapy-induced myelosuppression and a pipeline including trilaciclib in late-stage clinical trials for multiple oncology indications, positioning it within the competitive oncology drug development landscape.

What Is the Investment Thesis for GTHX?

G1 Therapeutics, Inc. presents an investment thesis centered on its dual approach of commercializing an approved product while advancing a diverse oncology pipeline. The company's lead commercial product, COSELA, addresses a significant supportive care need in extensive stage small cell lung cancer, providing a revenue stream and market presence. With a gross margin of 91.3%, COSELA demonstrates strong product-level profitability. The extensive Phase III clinical development of trilaciclib for first-line colorectal and triple-negative breast cancers represents a key near-term growth catalyst, with potential for substantial market expansion upon successful approval. Further pipeline assets like lerociclib and rintodestrant, along with strategic licensing agreements, offer additional long-term value drivers. While the company currently operates at a negative profit margin of -58.1% and has a market capitalization of $378M, successful advancement and commercialization of its pipeline candidates could significantly enhance its financial profile and market valuation, positioning G1 Therapeutics as a player in the oncology therapeutics sector.

Based on FMP financials and quantitative analysis

GTHX Key Highlights

Market capitalization stands at $378M, reflecting its position as a smaller-cap biotechnology company.

• Reported a gross margin of 91.3%, indicating strong profitability on its commercialized product, COSELA.
• Operates with a profit margin of -58.1%, typical for a clinical-stage biopharmaceutical company investing heavily in R&D.
• The company employs approximately 100 individuals, focusing resources on specialized drug discovery and development.
• Beta of 1.68 suggests higher volatility compared to the broader market, characteristic of the biotechnology sector.

Who Are GTHX's Competitors?

GTHX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GTHX's Key Strengths?

Commercialized product (COSELA) generating revenue with a high gross margin.

• Diverse and advanced clinical pipeline, including trilaciclib in multiple Phase III trials.
• Strategic licensing agreements expanding development and commercialization reach.
• Focused expertise in small molecule oncology therapeutics.
• Addressing critical supportive care needs and significant cancer indications.

What Are GTHX's Weaknesses?

Currently operating at a significant negative profit margin (-58.1%).

• Reliance on successful clinical trial outcomes for pipeline assets, which carry inherent risks.
• Relatively small market capitalization ($378M) compared to larger pharmaceutical companies.
• High research and development costs typical of the biotechnology sector.
• Limited commercial product portfolio with COSELA as the sole approved drug.

What Could Drive GTHX Stock Higher?

GTHX catalyst: Commercialization efforts for COSELA continue to drive revenue, with potential for increased market penetration in extensive stage small cell lung cancer.

• Anticipated data readouts from the Phase III clinical trials of trilaciclib for first-line colorectal cancer and first-line triple-negative breast cancer, expected to significantly impact future valuation.
• Further advancement of lerociclib into later-stage clinical trials or new licensing agreements that could expand its development and commercialization footprint.
• Progression of rintodestrant through its Phase IIa clinical trials for ER-positive and HER2-negative breast cancer, potentially leading to pivotal studies.
• Execution and potential expansion of existing strategic licensing agreements, which can provide non-dilutive funding and broader market access for G1's pipeline assets.

What Are the Key Risks for GTHX?

Financial-distress signal — its Altman Z-Score of -8.10 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-92.1%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for pipeline assets like trilaciclib, lerociclib, and rintodestrant could significantly impact future revenue potential and investor confidence.
• Regulatory approval risks, as there is no guarantee that pipeline candidates will successfully navigate the stringent approval processes of health authorities.
• Intense competition within the oncology market from well-established pharmaceutical companies with greater financial and commercial resources.
• The company's negative profit margin and reliance on external funding or future product sales to sustain operations and R&D investments.
• Market adoption challenges for COSELA or any future approved products, even after regulatory approval, due to competitive landscape, pricing pressures, or physician preferences.

What Are the Growth Opportunities for GTHX?

• **Expansion of COSELA's Market Penetration and Indications:** COSELA is currently approved for extensive stage small cell lung cancer to mitigate chemotherapy-induced myelosuppression. A significant growth opportunity lies in expanding its market share within this indication through enhanced commercial efforts and potentially exploring additional indications where myelosuppression is a concern across various chemotherapy regimens. Successful market penetration and any future label expansions could significantly increase revenue streams, capitalizing on the product's high gross margin and addressing broader supportive care needs in oncology. This ongoing opportunity is critical for establishing a stable commercial foundation.
• **Advancement and Commercialization of Trilaciclib:** Trilaciclib, a key pipeline asset, is in Phase III clinical trials for first-line colorectal cancer and first-line triple-negative breast cancer, representing substantial market opportunities. Positive data readouts from these pivotal trials, followed by successful regulatory submissions and approvals, would unlock access to multi-billion dollar markets. The drug's potential to improve patient outcomes in these aggressive cancers could drive significant revenue growth, transforming G1 Therapeutics from a single-product commercial company to one with multiple approved oncology therapeutics. The timeline for these advancements is tied directly to clinical trial progress and regulatory review.
• **Development and Licensing of Lerociclib:** Lerociclib, an oral CDK4/6 inhibitor, is being developed for multiple oncology indications. Its oral dosage form offers potential advantages in patient convenience and adherence compared to intravenous therapies. Further progress in its clinical development, potentially leading to new licensing agreements or direct commercialization, could open new therapeutic avenues and revenue streams for G1 Therapeutics. The existing license agreements with EQRx, Inc. and Genor Biopharma Co. Inc. for lerociclib's development and commercialization in certain territories underscore its global potential and strategic value.
• **Progression of Rintodestrant in Breast Cancer:** Rintodestrant, an oral selective estrogen receptor degrader, is in Phase IIa clinical trials for estrogen receptor-positive and HER2-negative breast cancer. This represents a significant opportunity in a large patient population, particularly for patients who may develop resistance to existing endocrine therapies. Successful progression through clinical development and potential commercialization could establish G1 Therapeutics in a competitive but lucrative segment of the breast cancer market. The oral formulation also offers a patient-friendly alternative to injectable SERDs, potentially enhancing market adoption.
• **Strategic Partnerships and Licensing Expansion:** G1 Therapeutics has demonstrated a strategy of leveraging partnerships, as evidenced by agreements for lerociclib with EQRx and Genor Biopharma, for trilaciclib with Nanjing Simcere Dongyuan Pharmaceutical Co., LTD., and for a CDK2 inhibitor with ARC Therapeutics. Expanding these strategic collaborations, either through new regional partnerships for existing assets or through new agreements for pipeline candidates, could provide non-dilutive funding, accelerate development, and broaden market access. These partnerships are crucial for sharing development risks and maximizing the global commercial potential of its therapeutic portfolio.

What Threats Does GTHX Face?

• Clinical trial failures, delays, or unexpected safety issues for pipeline candidates.
• Intense competition from larger pharmaceutical companies with established oncology portfolios.
• Regulatory hurdles and challenges in obtaining marketing approvals for new drugs.
• Intellectual property challenges or patent expirations affecting market exclusivity.
• Funding risks and the need for additional capital to support ongoing R&D and commercialization efforts.

What Are GTHX's Competitive Advantages?

• Proprietary small molecule therapeutics, including the approved COSELA and pipeline candidates like trilaciclib, lerociclib, and rintodestrant.
• Extensive clinical trial data and regulatory approvals for COSELA, establishing a market presence and efficacy profile.
• Intellectual property protection surrounding its novel compounds and their therapeutic applications in oncology.
• Specialized focus and expertise in oncology drug discovery and development, addressing specific unmet medical needs.
• Strategic licensing agreements that broaden development capabilities and market reach for its pipeline assets.

What Does GTHX Do?

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative small molecule therapeutics designed to improve outcomes for patients battling cancer. Incorporated in 2008 and headquartered in Research Triangle Park, North Carolina, the company has evolved to bring its first commercial product, COSELA, to market. COSELA is specifically indicated to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. This product addresses a critical unmet need by helping to protect the bone marrow during chemotherapy, potentially allowing patients to complete their treatment cycles with fewer complications. Beyond COSELA, G1 Therapeutics maintains a robust and diverse pipeline of oncology candidates. A key asset is trilaciclib, a CDK4/6 inhibitor currently undergoing extensive Phase III clinical trials for patients with first-line colorectal cancer and first-line triple-negative breast cancer. Additionally, trilaciclib is in Phase II clinical trials for patients with first-line bladder cancer, in combination with an antibody-drug conjugate, and for the treatment of neoadjuvant breast cancer. The company's pipeline also includes lerociclib, an oral CDK4/6 inhibitor being developed for multiple oncology indications, and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. G1 Therapeutics strategically leverages licensing agreements to expand its global reach and development capabilities, holding agreements with EQRx, Inc. and Genor Biopharma Co. Inc. for lerociclib, Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for trilaciclib, and ARC Therapeutics for a CDK2 inhibitor, solidifying its position in the competitive oncology therapeutic space.

What Products and Services Does GTHX Offer?

• Discover and develop small molecule therapeutics for cancer treatment.
• Commercialize COSELA to reduce chemotherapy-induced myelosuppression in extensive stage small cell lung cancer.
• Conduct Phase III clinical trials for trilaciclib in first-line colorectal cancer and triple-negative breast cancer.
• Advance trilaciclib through Phase II trials for bladder cancer and neoadjuvant breast cancer.
• Develop lerociclib, an oral CDK4/6 inhibitor, for various oncology indications.
• Progress rintodestrant, an oral selective estrogen receptor degrader, in Phase IIa trials for ER-positive/HER2-negative breast cancer.
• Engage in licensing agreements for the development and commercialization of its pipeline assets globally.
• Focus on improving patient outcomes in oncology through innovative small molecule therapies.

How Does GTHX Make Money?

• Generates revenue through the commercial sales of its approved product, COSELA.
• Receives payments from licensing agreements for the development and commercialization rights of its pipeline assets, such as lerociclib and trilaciclib.
• Invests in research and development to advance its clinical-stage pipeline, aiming for future drug approvals and commercialization.
• Seeks to expand its product portfolio through internal discovery and external partnerships.
• Aims to monetize successful clinical trial outcomes through product launches and market penetration in oncology.

What Industry Does GTHX Operate In?

G1 Therapeutics operates within the highly dynamic and competitive biotechnology industry, specifically focusing on oncology. The global oncology market is characterized by continuous innovation, significant unmet medical needs, and substantial investment in research and development. G1 Therapeutics positions itself by developing small molecule therapeutics, a segment known for its targeted mechanisms and potential for oral administration. The company's approved product, COSELA, addresses supportive care in cancer treatment, a niche but critical area. Its pipeline, particularly the CDK4/6 inhibitor trilaciclib, places it in direct competition with established and emerging players in breast cancer, colorectal cancer, and other solid tumor indications. The industry is driven by clinical trial success, regulatory approvals, and effective commercialization strategies, with market trends favoring personalized medicine and therapies that improve patient quality of life during treatment.

Who Are GTHX's Key Customers?

• Adult patients with extensive stage small cell lung cancer receiving specific chemotherapy regimens (for COSELA).
• Oncology healthcare providers and institutions administering chemotherapy and supportive care.
• Future patient populations with first-line colorectal cancer, triple-negative breast cancer, bladder cancer, and ER-positive/HER2-negative breast cancer upon pipeline approvals.
• Global pharmaceutical partners through licensing and collaboration agreements.
• Oncology specialists and medical oncologists prescribing cancer treatments and supportive care.

G1 Therapeutics, Inc. Financial Trajectory

G1 Therapeutics, Inc. (GTHX) reported $16.5M in revenue for Jun 2024, reflecting 14.3% growth compared to the prior quarter. The company recorded a net loss of $5.5M, with diluted EPS of $-0.10.

Company Profile

G1 Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Research Triangle Park, US. The company is led by CEO John E. Bailey Jr.. GTHX has traded publicly since 2017.

How G1 Therapeutics, Inc. Is Valued

G1 Therapeutics, Inc. carries a market capitalization of $378M, placing it in the small-cap category.

Return on equity for G1 Therapeutics, Inc. stands at -92.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.9%, the inverse of the P/E and a quick read on earnings relative to price.

G1 Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.10 places it in the distress zone, a signal of elevated financial risk.

G1 Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 31.0% above estimates on average.

Wall Street analysts project G1 Therapeutics, Inc. revenue of about $672.3M for fiscal 2026, with EPS near $10.18. The estimate reflects 3 contributing analysts.

The most recent 12 insider filings for G1 Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 551K shares disposed (about $2.4M), a signal worth weighing alongside the fundamentals.

GTHX Financials

GTHX Latest News

What Investors Ask About G1 Therapeutics, Inc. (GTHX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources